Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.

Birnbaum Y, Castillo AC, Qian J, Ling S, Ye H, Perez-Polo JR, Bajaj M, Ye Y.

Cardiovasc Drugs Ther. 2012 Dec;26(6):445-56. doi: 10.1007/s10557-012-6409-x.

PMID:
22936458
2.

Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.

Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y.

Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H131-41. doi: 10.1152/ajpheart.00609.2012. Epub 2012 Oct 26.

4.

The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.

Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, Birnbaum Y.

Cardiovasc Drugs Ther. 2007 Oct;21(5):321-30.

PMID:
17620005
5.

PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins.

Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, Bajaj M.

Cardiovasc Drugs Ther. 2014 Oct;28(5):447-57. doi: 10.1007/s10557-014-6546-5.

PMID:
25106875
6.

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y.

Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1454-65. doi: 10.1152/ajpheart.00867.2009. Epub 2010 Mar 5.

7.
8.

Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase A-dependent pathway in infarcted hearts.

Lee TM, Chen WT, Chang NC.

Circ J. 2015;79(11):2461-70. doi: 10.1253/circj.CJ-15-0515. Epub 2015 Sep 24.

9.

Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.

Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y.

Cardiovasc Drugs Ther. 2011 Dec;25(6):505-15. doi: 10.1007/s10557-011-6339-z.

PMID:
21987107
10.

Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.

Wada T, Onogi Y, Kimura Y, Nakano T, Fusanobori H, Ishii Y, Sasahara M, Tsuneki H, Sasaoka T.

Eur J Pharmacol. 2013 May 5;707(1-3):120-9. doi: 10.1016/j.ejphar.2013.03.016. Epub 2013 Mar 22.

PMID:
23528355
11.

Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway.

Li XD, Yang YJ, Geng YJ, Zhao JL, Zhang HT, Cheng YT, Wu YL.

Acta Pharmacol Sin. 2012 Jul;33(7):879-87. doi: 10.1038/aps.2012.27. Epub 2012 Jun 4.

12.

Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL.

Endocrinology. 2012 Feb;153(2):564-73. doi: 10.1210/en.2011-1732. Epub 2011 Dec 20.

PMID:
22186413
13.

Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery.

Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DD, Cook RC, Fradet G, Au CL, Ansley DM.

Clin Endocrinol (Oxf). 2011 Jun;74(6):705-13. doi: 10.1111/j.1365-2265.2011.03979.x.

14.

Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.

Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C, Uretsky BF, Poh KK, Tan HC, Fujise K.

Cardiovasc Drugs Ther. 2011 Jun;25(3):223-32. doi: 10.1007/s10557-011-6302-z.

15.

Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.

Sanganalmath SK, Barta J, Takeda N, Kumamoto H, Dhalla NS.

Can J Physiol Pharmacol. 2008 Apr;86(4):180-9. doi: 10.1139/Y08-005.

PMID:
18418427
16.

PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow.

Li XD, Cheng YT, Yang YJ, Meng XM, Zhao JL, Zhang HT, Wu YJ, You SJ, Wu YL.

Microvasc Res. 2012 Jul;84(1):44-54. doi: 10.1016/j.mvr.2012.04.002. Epub 2012 Apr 14.

PMID:
22542438
17.

Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway.

Chen WJ, Chen YH, Lin KH, Ting CH, Yeh YH.

Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2106-13. doi: 10.1161/ATVBAHA.111.230987. Epub 2011 Jun 16.

18.

Cilostazol promotes production of melanin by activating the microphthalmia-associated transcription factor (MITF).

Wei B, Zhang YP, Yan HZ, Xu Y, Du TM.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):617-21. doi: 10.1016/j.bbrc.2013.12.017. Epub 2013 Dec 11.

PMID:
24333333
19.

Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells.

Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, Ouchi Y.

Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1634-9. doi: 10.1161/ATVBAHA.108.164368. Epub 2008 Jun 12.

20.

Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis.

Ke K, Safder AM, Sul OJ, Suh JH, Joe Y, Chung HT, Choi HS.

PLoS One. 2015 May 18;10(5):e0124869. doi: 10.1371/journal.pone.0124869. eCollection 2015.

Supplemental Content

Support Center